WO2021206741A1 - Modulating neurotransmitter concentration - Google Patents
Modulating neurotransmitter concentration Download PDFInfo
- Publication number
- WO2021206741A1 WO2021206741A1 PCT/US2020/035029 US2020035029W WO2021206741A1 WO 2021206741 A1 WO2021206741 A1 WO 2021206741A1 US 2020035029 W US2020035029 W US 2020035029W WO 2021206741 A1 WO2021206741 A1 WO 2021206741A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecule
- receptor
- bind
- concentration
- flexibility
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Each receptor in question should be bound to only one molecule. The current approach is to create a molecule that 'does it all'. The most effective, efficient, and easy way to modulate the concentration of neurotransmitters in the body is to be specific, one molecule should only bind to one receptor. The current method uses molecules that bind the receptor in many different active sites which does not allow for flexibility or proper and precise modulation. Neuroscience: Each receptor in question should be bound to only one molecule. The current approach is to create a molecule that 'does it all'. The most effective, efficient, and easy way to modulate the concentration of neurotransmitters in the body is to be specific, one molecule should only bind to one receptor. The current method uses molecules that bind the receptor in many different active sites which does not allow for flexibility or proper and precise modulation.
Description
(A) Specification
Modulating Neurotransmitter Concentration
B: Cross Reference to Related Applications: Not Applicable
( C ) Regarding Federally Sponsored Research or Development: Not Applicable
( D): Regarding The Names of The Parties To a Joint Research Agreement: Not Applicable
E: Incorporation by reference of material submitted on a compact disc or as a text file via the The Office Electronic Filing System (EFS-Web):
F: Statement Regarding Prior Disclosures by The Inventor Or a Joint Inventor:
Not Applicable
G: Background of Invention:
(1): Organic Chemistry: As the molecule binds to the active site of the subunit In question and modulates the enzyme to a transition state.
(2): Neuroscience: Each receptor in question should be bound to only one molecule. The current approach is to create a molecule that 'does it all'. The most effective, efficient, and easy way to modulate the concentration of neurotransmitters in the body is to be specific, one molecule should only bind to one receptor. The current method uses molecules that bind the receptor in many different active sites which does not allow for flexibility or proper and precise modulation.
(H): Brief Summary of Invention: One molecule should bind to one active site. Molecules that bind to multiple active sites decreases the effectiveness of the molecule to do what we want it to. Modulation of receptors in this way allows for flexibility in adjusting doses, dissociation constants, and joint collaboration with the other molecules being used for a specific purpose. This novel technique introduces specificity into the environment of modulation.
(K): Claim or Claims: See Document "Claims"
(L): Abstract of Disclosure: See Document "Abstract"
(M): Sequence Listing: Not Applicable
Claims
Claims:
I:Using one molecule for one receptor subunit provides greater specificity and flexibility to modulate neurochemistry.
II: Dosages can be adjusted to work in concert with other molecules bound to their receptors.
III: This novel technique allows for the development of better therapies as one molecule is not binding to multiple receptors at a state people cannot control with precision.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007943P | 2020-04-09 | 2020-04-09 | |
| US63/007,943 | 2020-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021206741A1 true WO2021206741A1 (en) | 2021-10-14 |
Family
ID=78023055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2020/035029 WO2021206741A1 (en) | 2020-04-09 | 2020-05-29 | Modulating neurotransmitter concentration |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2021206741A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040213816A1 (en) * | 2003-01-16 | 2004-10-28 | Weiner David M. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| US20070197480A1 (en) * | 2003-12-18 | 2007-08-23 | Srz Properties, Inc. | (S)-2-N-Propylamino-5-Hydroxytetralin As A D3-Agonist |
| US20160158204A1 (en) * | 2013-07-01 | 2016-06-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord motor disorders |
-
2020
- 2020-05-29 WO PCT/US2020/035029 patent/WO2021206741A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040213816A1 (en) * | 2003-01-16 | 2004-10-28 | Weiner David M. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| US20070197480A1 (en) * | 2003-12-18 | 2007-08-23 | Srz Properties, Inc. | (S)-2-N-Propylamino-5-Hydroxytetralin As A D3-Agonist |
| US20160158204A1 (en) * | 2013-07-01 | 2016-06-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord motor disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4342912A3 (en) | Binding molecules that modulate a biological activity expressed by a cell | |
| CY1110579T1 (en) | THE FUNCTIONALITY OF A TROUBLE-BLOOD HOLDER AND ITS USES | |
| ATE517123T1 (en) | ANTI-GPR-9-6 AND ANTI-TECK TARGETED ANTIBODIES AND METHOD FOR IDENTIFYING MODULATORS OF THE GPR-9-6 AND TECK FUNCTION | |
| AR019628A1 (en) | METHOD FOR IDENTIFYING NEW MULTIMERIC AGENTS THAT MODULATE RECEPTORS. | |
| DE69233724D1 (en) | Binding domains of the Serrate protein | |
| DE602005021968D1 (en) | PEER-TO-PEER ENGINE FOR THE COMMON USE OF OBJECTS IN COMMUNICATION DEVICES | |
| NO20082381L (en) | Bispecific ligands with binding specificity to cell surface template and methods for using them | |
| AU2020224154A8 (en) | Multifunctional molecules that bind to calreticulin and uses thereof | |
| WO2021206741A1 (en) | Modulating neurotransmitter concentration | |
| NO980198L (en) | Modulators of the function of FAS receptors and other proteins | |
| MX2023006969A (en) | Gucy2c binding molecules and uses thereof. | |
| WO2022229919A3 (en) | Bispecific pd-1 and tigit binding proteins and uses therof | |
| MX2023004439A (en) | CANINIZED ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR <i>ALPHA. | |
| BR112022022353A2 (en) | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING CD70-SPECIFIC FUSION PROTEINS | |
| DK1754713T3 (en) | Peptides that bind to Apo2L (Trail) receptors and their applications | |
| JOP20220025A1 (en) | Materials and methods for polymeric antibody receptor targeting | |
| WO2024168061A3 (en) | Antibody molecules binding to sars-cov-2 | |
| Joyce et al. | Copyright Law | |
| Guerzovich et al. | The politics of open contracting for urban service delivery: Brazilian contexts, strategies, and learning | |
| Patil | Thiocyanate degradation by pure and mixed bacterial cultures | |
| WO2024129862A3 (en) | Checkpoint modulators for enhancing immunotherapy | |
| WO2023115029A3 (en) | Antibody-based depletion of il1r2-positive cells | |
| Subburayan | The Pragyan Rover and Presence of Sulphur on Moon: Why It Holds Substantial Significance | |
| Afrin et al. | Amino Acids Adsorption to Mineral Surfaces: Basis for Prebiotic Molecule Accumulation Studied at Nanoscale | |
| WO2024102421A3 (en) | Compounds, complexes, and methods for their preparation and of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20930135 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20930135 Country of ref document: EP Kind code of ref document: A1 |